Abstract Introduction: Incidence of follicular lymphoma (FL) increases with age and patients (pts) often relapse, requiring multiple lines of therapy. Tafasitamab (tafa), a humanized CD19-targeting monoclonal antibody (mAb), in combination with lenalidomide (len) + rituximab (R) was recently approved for treatment of adults with relapsed or refractory FL (R/R FL) in the US. At the primary analysis of inMIND (NCT04680052), an international, phase 3, double-blind, randomized, placebo (pbo)-controlled trial, tafa+len+R demonstrated a significant improvement in PFS in pts with R/R FL with a 57% reduction in the risk of progression or death and a safety profile as expected in the pt population (Sehn LH, et al. Blood. 2024;144Suppl 2:LBA1). This post hoc analysis evaluates efficacy and safety in pts enrolled in inMIND by age. Methods Eligible pts were aged ≥18 y with R/R CD19+ and CD20+ FL (grade 1-3A) and ECOG PS ≤2, who had received ≥1 prior systemic therapy including an anti-CD20 mAb. Pts were randomized 1:1 to receive tafa 12 mg/kg IV or pbo with standard dosing of len+R for up to 12×28-day cycles. Pts with moderate renal insufficiency (CrCl ≥30 to 60 mL/min) were also eligible and received a reduced starting dose of len at 10 mg daily. Analyses included PFS by investigator (primary endpoint) and safety in pts 65 y and ≥65 y, and in pts 75 y and ≥75 y. Results Overall, 548 pts were randomized to the tafa arm (n=273) or pbo arm (n=275). Of the total pts enrolled in both treatment arms, 50% were 65 y (tafa, n=137; pbo, n=139), 50% were ≥65 y (tafa, n=136; pbo, n=136), 80% were 75 y (tafa, n=219; pbo, n=221), and 20% were ≥75 y (tafa, n=54; pbo, n=54). Baseline characteristics were generally similar between the tafa and pbo arms within age categories; median time since FL diagnosis (65 y, 4.6 y and ≥65 y, 6.4 y; 75 y, 5.1 y and ≥75 y, 6.7 y) and proportions of pts with FLIPI score ≥3 (65 y, 40% and ≥65 y, 65%; 75 y, 50% and ≥75 y, 64%) were higher in pts ≥65 y vs 65 y and ≥75 y vs 75 y. Proportions of pts with CrCl 30 to 60 mL/min were 5% and 34% in pts 65 y and ≥65 y and 11% and 52% in pts 75 y and ≥75 y, respectively. For pts 65 y, median investigator-assessed PFS was not reached with addition of tafa vs 12.0 months with pbo (hazard ratio HR 95% CI 0.35 0.22, 0.55), and for pts ≥65 y was 20.0 months with tafa vs 15.0 months with pbo (HR 95% CI 0.53 0.35, 0.80). Improvements were also observed in pts 75 y and ≥75 y: median investigator-assessed PFS was 23.6 months with addition of tafa vs 14.4 months with pbo (HR 95% CI 0.44 0.31, 0.61) for pts 75 y, and 15.0 months with addition of tafa vs 13.0 months with pbo (HR 95% CI 0.58 0.30, 1.12) in pts ≥75 y. The small number of pts ≥75 y limits interpretation of these data. TEAEs were reported for 98% of pts in the tafa or pbo arm across age subgroups. Grade 3 or 4 TEAEs were reported for 66% of pts 65 y in the tafa arm and 65% of pts in the pbo arm, and for 76% of pts ≥65 y in the tafa arm and 75% of pts in the pbo arm. Serious TEAEs were reported for 34% of pts 65 y in the tafa arm and 30% of pts in the pbo arm, and for 39% of pts ≥65 y in the tafa arm and 34% of pts in the pbo arm. Fatal TEAEs occurred in 1 pt (1%) 65 y in both the tafa and pbo arms and in 5 pts (4%) ≥65 y in both the tafa and pbo arms. Tafa or pbo discontinuations due to TEAEs were recorded for 10% and 6% of pts 65 y, and for 12% and 8% of pts ≥65 y in the tafa and pbo arms, respectively. Grade 3 or 4 TEAEs were reported for 69% and 68% of pts 75 y and for 80% and 74% of pts ≥75 y in the tafa and pbo arms, respectively. Serious TEAEs were reported for 35% of pts 75 y in the tafa arm and 28% of pts in the pbo arm, and for 41% of pts ≥75 y in the tafa arm and 44% of pts in the pbo arm. Fatal TEAEs occurred in 4 pts (2%) and 2 pts (4%) 75 y, and in 3 pts (1%) and 3 pts (6%) ≥75 y in the tafa and pbo arms, respectively. Tafa or pbo discontinuations due to TEAEs were reported for 10% of pts 75 y in the tafa arm and 6% of pts in the pbo arm, and for 17% of pts ≥75 y in the tafa arm and 11% of pts in the pbo arm. Data on tafa and len dose reduction will be presented. Conclusions This analysis confirms that tafa+len+R reduced risk of progression or death measured by PFS irrespective of pt age, including older pts up to 88 y and with moderate renal insufficiency. The safety profile was manageable across older and younger pts with toxicities as expected for the pt population.
Wu et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: